Curasight
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreLatest research
Latest analysis report
Released: 2025-01-21
Curasight: Year-end report Q4 2024
Curasight announces an updated financial calendar 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account

Curasight (One-pager): Extensive pipeline milestones in 2025
Participation in warrant exercise by Curasight management
Curasight A/S announces outcome of warrant exercise
Curasight: SEB maintain valuation range midpoint at DKK 54 per share
Curasight: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024
BioStock: Curasights vd reflekterar över starkt Q3
BioStock: Curasight CEO reflects on a Q3 with strong progress
Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]

Curasight: Q3 report and exercise period in warrant TO2 starts
Curasight: The exercise period for warrants of series TO2 commences today
Curasight: Interim report Q3 2024
Curasight: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share
